Is Now the Perfect Time to Invest in These Undervalued Blue-Chip Stocks?

TipsForTraders | March 21, 2024

Responsive image

Minting substantial returns from the market often hinges on the strategic selection of stocks, coupled with patience and a keen eye for undervalued opportunities. This analysis delves into the realm of blue-chip stocks that have not seen significant movement in recent times but are on the brink of potentially robust growth. Despite their current stagnation, these stocks exhibit traits of undervaluation, making them ripe for investment. With the anticipation of business and growth catalysts on the horizon, these companies are expected to perform exceedingly well, surpassing index returns in the forthcoming 24 months.

Lockheed Martin (NYSE:LMT) has experienced a 7% decrease over the past year, yet it has shown a commendable 48% return over the past five years. Currently, it appears undervalued with a forward price-earnings ratio of 16.8 and an enticing dividend yield of 2.88%. The bullish outlook for Lockheed Martin is fueled by the global uptick in defense spending, which reached a new zenith of $2.2 trillion in 2023. With NATO members ramping up their defense budgets, Lockheed Martin stands to gain significantly. The company’s record backlog of $160.6 billion at the end of 2023 positions it for accelerated revenue growth, potentially driving its stock price upwards. Additionally, Lockheed Martin’s commitment to free cash flow, projected at $6.2 billion for the year, promises ongoing shareholder value through dividends and share buybacks.

AstraZeneca (NASDAQ:AZN), another contender in the stagnating blue-chip arena, is undervalued at a forward price-earnings ratio of 15.7, with a dividend yield of 2.2%. The post-pandemic world has overlooked biopharmaceutical stocks, yet AstraZeneca’s diversified drug portfolio addresses a broad spectrum of global health issues. With 178 projects in its pipeline and 17 late-stage molecular entities, the company is on the verge of breakthroughs that could significantly boost revenue in the near future. AstraZeneca’s 35% year-on-year growth in emerging markets (excluding China) in 2023 underscores its global diversification and potential for sustained growth.

Occidental Petroleum (NYSE:OXY) has seen a 9% increase in stock price over the last year, attributed to recent gains. With an undervaluation and a dividend yield of 1.37%, Occidental is poised for further appreciation. The recent surge in oil prices to an 11-month high, alongside continued OPEC production cuts and geopolitical tensions, suggests a favorable outlook for Occidental. The company’s investment-grade balance sheet and a reported $5.5 billion in free cash flow last year provide a solid foundation for dividend growth, share repurchases, and exploration investments. Endorsed by Warren Buffett, Occidental Petroleum is set to create significant value for investors in the near term.


The detailed examination of Lockheed Martin, AstraZeneca, and Occidental Petroleum highlights their potential to break out of stagnation and achieve substantial growth. These undervalued blue-chip stocks, backed by solid business fundamentals and poised for upcoming positive catalysts, present compelling opportunities for investors seeking to diversify their portfolios and harness exceptional returns. With strategic investments in these companies, investors can look forward to reaping the benefits of their resurgence and market outperformance in the next couple of years.